Member Info for Bigears1170

😃 Theres life in the old dog yet 🐶🤣

The AIM defibrillator me thinks 😲

Really ? I thought yesterday’s were from January

From November 2024

Page 1

Evening all,

As promised, herewith my notes from the call with Shaun and Chris earlier this evening.

To avoid the notes from the call being taken out of context, I thought a series of factual/clear bullet points would be preferable for this group, which is clearly craving some certainty with the share price where it is:

- Chris and Shaun are highly aware of the impact the CLN is having. It is top of their in-tray and there is not a day which goes by where they do not talk about it. I am confident they are giving it the attention it deserves and they appreciate the optics. They asked us to be patient in this regard. They are well aware of our desire to appoint a co-broker and indicated action would be taken which addresses these concerns.

- Taking preCISION from a peptide and a drug to a 'system' should not be overlooked. In order to solve the issues which Doxorubicin and Exatecan face (toxicity) we needed a sustained release mechanism (in the tumour). That leap (i.e. from harnessing Doxorubicin to Exatecan) should not be underestimated from an achievement and workload perspective. Avacta filed this patent in October 2024. They do not have to discuss this patent until it publishes in October 2025. There are very few drugs (Doxorubicin is one) which do not require this additional patent protection. This is why Avacta could not disclose AVA6103 until the patent had been submitted.

Partnership discussions on 6103 could not begin until this protection was in place.

- Dx is on track. Shaun noted everything is taking longer to close right across VC/PE/listed. But this does not indicate issues. Again, they asked for some additional patience here.

- There is a lot of background work going on with AVA6000 which we cannot see and they cannot talk about. Everything is being planned. They understand the TNBC landscape intimately.

- On the TNBC Arm they are looking at 20+ patients. Stressed this is a very good number. Most oncologists believe 12 is the number (10 is too few; 15 is considered a lot for a very specific patient population like TNBC). Based on Bayesian statistics. Dosing is on track for Q4.

- Collaboration on AVA6000. It is often overlooked how much knowledge we have built up. If we were to partner AVA6000 (in any indication) we have the knowledge. That cannot be bought without a takeover. Noted any partnership deals create a competitor. They (i.e. that prospective partner) don't want to share TNBC with us (we should remember that).

- TNBC has always been Chris' plan. It is the major prize for AVA6000. Everything was building towards this. The challenge was proving to the investigators they would not be sending their patients for heart failure treatment. Chris remarked she does not need an animal model to know AVA6000 will work with TNBC because Doxorubicin is used in this indication and the STS/SGC responses are exciting enough to push them into TNBC.

- The two-week regimen was to show lower dose

Page 2

This was to enable future combo trials. The entire structure of the bi-weekly was to enable Avacta to go into combination therapy trials with 6000. Again, completely unappreciated by the market.

- There is no risk of the UK listing being removed in the short term (both retail and institutional investors have asked this question of Avacta). It's clear they are working incredibly hard and have our best interests at heart. They finished with 'we wish we could tell you everything that is going on as it would all make more sense, but as you know we can't...

As ever, please do not share/ reference these notes beyond this group.

Thanks,

Mark (on behalf of Admin)

How long before 0.75p looks like the great escape 😳

Mark Mitchell

Good Morning

Ax promised , here are my more comprehensive notes from yesterday call ( believed to have taken place 17th Jan 2025 ) which lasted just over 40 minutes .

The purpose of Chris requesting the call was to contextualise just how good the data is. She ( quite impressively in my view) foresaw some – as many did on telegram yesterday – would not see this data for what it is : the makings of AVA6K in SGC which has no standard of care.

Avacta has been heavily at work on the approved strategy for AVA6K over the past few months, Yesterdays RNS ( believed to be 16th Jan ) ) conveyed what Chris called a “ hidden message for institutional investors and BP “. The RNS put them on notice we are going to seek an accelerated route for SGC ..IE so they see we have a strategy in place .

Avacta are screening lots of patients in P1b . I did not get a chance to ask whether the withpower figures shareholders have quoted on here are correct but I got the impression from her enthusiasm around recruitment and regular references to multiple sites they probably are.

Avacta had hoped to announce the dosing of P1b yesterday ( believed to be 16th Jan ) in tandem with the RNS but it was slightly delayed ( thus imminent really does mean imminent).

We can expect an R&D spotlight over the next week or two on AVA6103 ( this happened 29th Jan ) and Chris reiterated there would be two more important RNS before the end of January ( Clearly didn’t happen ) .

I assume one is DX. I do not know what the other event could be.

They continue to speak to Co Brokers .

They met with Richard Hughes of Zeus Capital last week so I assume we will also hear on a UK co broker shortly.

Back to SGC and why Chris believes it’s likely the “ one which will pull away from the pack “ . Again , she referenced the lack of guidelines for SGC. The box for “preferred regime “ under metastic SGC is blank, there is no standard of care.

There are very few cancers where the guidelines are blank. The advantage here is the FDA cannot ask Avacta to use drug X as a comparator for the trial. This enables much more flexibility for Avacta when designing the trial endpoints, which as we all know is crucial.

This is the full text which I found on X yesterday and is a copy of a chain of text messages which are allegedly the contents of a telephone a conversation between a gentleman by the name of Mr Mark Mitchell and our CEO Christina Coughlin – this is publicly available information – no investment advice implied or given

The investigators are all heavily involved in our planning here.it is also likely ( and this is more subtext to yesterday’s announcement mid Jan ) that we will be able to move very quickly in terms of an accelerated route to approval , she did not say how quick and I did not ask as she was in full flow at this point. On to the data “ it really is tremendous “ The patients were mainly enrolled over September & October . “ as you can imagine when the CT scans started to roll in we couldn’t believe it , they were not only dramatic but consistent , Chis noted that often SGC has weird metastatic patients so this consistency in efficacy was really quite noticeable.

Missing Text ( I’m sure Somone hereabouts could fill in the dots here )

But also whether we want to retain 100% of an indication which is likely to move very quickly through an accelerated approval route. “ so we can start to book revenue ASAP “

Pharma are actively looking at the data now under NDA. This was one of the reasons Chris was in San Francisco this week.

For Chris what has been most important is a clear correlation in this SGC data. Its clear the trend was what has excited her along with the consistency of results. “ We couldn’t believe it “. That metastasis has seen a complete regression . Crucially , the way RECIST measures SGC doesn’t enable this dramatic shrinkage to be valued in a meaningful / representative way. Chris remarked when we see the photo it will hit home far harder. This data will be accompanied by a video presentation. It could not happen this week as Chris has been so busy preparing for San Francisco meetings.

On partnerships , she reiterated its like dating. Its also clear they are considering a range of options from multi indications deals to individual indications . Again all led by the …….. Missing Text ( I’m sure Somone hereabouts could fill in the dots here ) .

Fundamentally , its obvious this was the moment Avacta started to get really excited about AVA6K.

Its going to be a very exciting few weeks/ months ahead.

We haven’t even got going in the first line setting yet.

Best Mark

It’s not the update anyone wanted , but it’s the bone Christina Coughlin chose to throw to her chosen few in the medium of her choice.

We all know it happens , but for her to be singing like a canary down the blower to some dude who types it out and distributes it to planet earth reeks of unprofessionalism and rank amateurism …

Not so quiet after all is she ……

Yesterdays RNS ( mid Jan ) conveyed what Chris called a “ hidden message for institutional investors and BP “. The RNS put them on notice we are going to seek an accelerated route for SGC ..IE so they see we have a strategy in place . Avacta are screening lots of patients in P1b . I did not get a chance to ask wether the withpower figures shareholders have quoted on here are correct but I got the impression from her enthusiasm around recruitment and regular references to multiple sites they probably are.

Avacta had hoped to announce the dosing of P1b yesterday ( mid Jan ) in tandem with the RNS but it was slightly delayed ( thus imminent really does mean imminent).

Of course she can , not a good look though is it ….

The investigators are all heavily involved in our planning here.it is also likely ( and this is more subtext to yesterday’s announcement mid Jan ) that we will be able to move very quickly in terms of an accelerated route to approval , she did not say how quick and I did not ask as she was in full flow at this point. On to the data “ it really is tremendous “ The patients were mainly enrolled over September & October . “ as you can imagine when the CT scans started to roll in we couldn’t believe it , they were not only dramatic but consistent , Chis noted that often SGC has weird metastatic patients so this consistency in efficacy was really quite noticeable

Quite interesting posts from mid Jan ….. she telegraphed the End of Jan R&D spotlight ….

“ Pharma are actively looking at the data now under NDA, this was one of the reasons Chris was in San Francisco this week “

What a gal …… unprofessional & unethical

You see this is my point.

If we can agree that these posts are not a fabrication and that CC has indeed been briefing a Telegram group ( FWIW I know she is & I don’t doubt some here are part of the group )

She requested ( which has been paraphrased) a call which lasted 40mins which in part was to to contextualise just how good the data is , and that she foresaw that many would not see the data for what it is , that being the makings of AVA6k in SGC ……. So why does she not have the right PR smashing this in to the market 🫤

Yep ….. I’ve just seen that , rather annoying imho

ok - i apologise. i don’t mean to **** folk off - but i just call a spade a spade - 🤐

what news am i / was i expecting ?

i’ll tell you what i expect of cc , absolutely fcuk all …..metaphorically speaking she is sat waiting for the drillers to strike a sea of oil , she will then pop up with her cheshire cat 😁 grin and take all the scientists credit that comes her way.

if the sp was sitting at £2.00 this evening coughlin would be being given ( and excepting ) all of the plaudits for the rise. yet the sp sits circa 12% lower than the day she arrived and pi’s put it down to , its just “one of those things “ , or it’s “the pesky aim “ etc etc …. you can’t have it both ways.

she has had all the good fortune in the world to date , every bit of news she had to release has been the stuff of most biotech ceos dreams … the fact is she and her team have failed to cultivate that news in a way that translates sentiment and progress to the market, it’s is an absolute disgrace , its undeniable and demonstrable by todays sp.

not only has she failed to sell the data and its story to the market , she has either been too bone idle, been unwilling ,or incapable of finding a home for some or all of the quarterly cln stock ….again a ******* disgrace and unacceptable.

she is an amateur ceo on every level outside the laboratory and i believe ( unfortunately) it will manifest itself sooner or later.

so what am i expecting ? not a lot really , the sp will keep drifting south untill dx is flogged , if we get north of £20m it will be hailed as a cc master stroke , if we get south of £20 the narrative will be sb did what he could in a buyers market ………

roll on p1b ….. and as our charlatan ceo would say, stay toooned ……

The share price is driven by good company communication which in turn promotes sentiment amongst the investment community- we have shocking comms which has a detrimental effect on the sp .

Whats happening with this mutt 🐶 this afternoon ?

Their PR is shocking on every level --- But Christina Coughlin is happy to converse with selective private investor groups .

Agreed - When has any shareholder with half of a head wanted their CEO to strike the wrong deal ? Not striking a deal is no excuse for a non existent public relations strategy .